Clinical Study of PD-1 Inhibitor Combined with Albumin Bound Paclitaxel,Platinum in the Treatment of Advanced Esophagus Cancer
Objective:To investigate the clinical effect of programmed death-1(PD-1)inhibitor combined with Albumin Bound Paclitaxel,Platinum in the treatment of advanced esophagus cancer.Method:A total of 82 patients with advanced esophagus cancer admitted to General Hospital of Huainan Oriental Hospital Group from December 2020 to December 2022 were selected and divided into study group and conventional group according to random number table,with 41 cases in each group.The conventional group was treated with Albumin Bound Paclitaxel and Platinum,and the study group was treated with PD-1 inhibitor on the basis of the conventional group.Clinical efficacy and adverse reactions,cytokeratin 19 fragment(Cyfra 21-1)and squamous cell carcinoma antigen(SCCA)levels were compared between the two groups,progression free survival(PFS)was compared between the two groups after 1 year of follow-up.Result:The disease control rate(DCR)and objective remission rate(ORR)in the study group were higher than those in the conventional group(P<0.05).Compared with before treatment,Cyfra 21-1 and SCCA were decreased in both groups,and those in study group were lower than those in conventional group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The median PFS in study group was longer than that in conventional group(P<0.05).Conclusion:PD-1 inhibitor combined with Albumin Bound Paclitaxel,Platinum have a significant effect in the treatment of advanced esophagus cancer patients,which can reduce Cyfra 21-1 and SCCA levels and improve prognosis.
国家科技期刊平台
NSTL
万方数据
